Innovative
Therapeutics for
Better Health
Because Life
Shouldn't Have to
Wait for Migraines
Our Lead Product Candidate
STS101
Dihydroergotamine (DHE) Nasal Powder
Learn More
Clinical Trials
SUMMIT™ Trial
Currently Recruiting
Learn More
Press Releases
Oct 12, 2021
Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors
Read More
Sep 28, 2021
Satsuma Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
Read More
